ACIP meeting focuses on HPV, influenza, meningococcal vaccines, much more

Influenza vaccines: more options and more opportunities.

Influenza, whether seasonal or pandemic, causes substantial morbidity and mortality. Today, vaccines are the foundation of influenza prevention. Globally, influenza vaccine manufacturing capacity is at an all-time high [1], as are the number and types of influenza vaccines available on the market and in development. In the United States, in addition to the live attenuated and inactivated subuni...

Control of meningococcal meningitis with meningococcal vaccines.

The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies. Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity. In controlled field trials in Army...

Advances in meningococcal vaccines

Meeting Report: Summit Focuses on Pharmaceuticals in Drinking Water

Keeping our drinking water clean and contaminant-free is a concern of many policy makers and scientists, and it was the headlining topic at the inaugural Environmental Health Summit of the Research Triangle Environmental Health Collaborative held 10–11 November 2008 in Research Triangle Park, North Carolina. With nearly 150 attendees representing government, research, academia, public interest ...

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

An influenza pandemic will place an enormous strain on the world's vaccine production, distribution and administration systems. Following a pandemic declaration, industry's priority will be to deliver as much vaccine in as short a timeframe as possible. In respect to this challenge, manufacturers have successfully developed antigen-sparing strategies and significantly increased production capac...